These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 2151275

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
    Denis L, Smith PH, De Moura JL, Newling DW, Bono A, Keuppens F, Robinson M, Mahler C, Sylvester R, De Pauw M.
    Eur Urol; 1990; 18 Suppl 3():34-40. PubMed ID: 2151274
    [Abstract] [Full Text] [Related]

  • 3. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
    Iversen P, Christensen MG, Friis E, Hornbøl P, Hvidt V, Iversen HG, Klarskov P, Krarup T, Lund F, Mogensen P.
    Cancer; 1990 Sep 01; 66(5 Suppl):1058-66. PubMed ID: 2144207
    [Abstract] [Full Text] [Related]

  • 4. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
    Iversen P, Suciu S, Sylvester R, Christensen I, Denis L.
    Cancer; 1990 Sep 01; 66(5 Suppl):1067-73. PubMed ID: 2144208
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
    Robinson MR, Denis L, Newling DW, Sylvester R, De Pauw M.
    Cancer; 1990 Sep 01; 66(5 Suppl):1022-4. PubMed ID: 2144204
    [Abstract] [Full Text] [Related]

  • 7. Comparability of EORTC and DAPROCA studies in advanced prostatic cancer.
    Suciu S, Sylvester R, Iversen P, Christensen I, Denis L.
    Cancer; 1990 Sep 01; 66(5 Suppl):1029-34. PubMed ID: 2144205
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer.
    Iversen P, Rasmussen F, Klarskov P, Christensen IJ.
    Cancer; 1993 Dec 15; 72(12 Suppl):3851-4. PubMed ID: 8252502
    [Abstract] [Full Text] [Related]

  • 12. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
    Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, Sylvester R, Armitage TG.
    Cancer; 1990 Sep 01; 66(5 Suppl):1009-16. PubMed ID: 2144203
    [Abstract] [Full Text] [Related]

  • 13. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
    Jurincic CD, Horlbeck R, Klippel KF.
    Semin Oncol; 1991 Oct 01; 18(5 Suppl 6):21-5. PubMed ID: 1835139
    [Abstract] [Full Text] [Related]

  • 14. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
    Cooper EH, Armitage TG, Robinson MR, Newling DW, Richards BR, Smith PH, Denis L, Sylvester R.
    Cancer; 1990 Sep 01; 66(5 Suppl):1025-8. PubMed ID: 1697498
    [Abstract] [Full Text] [Related]

  • 15. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ, Denis L, de Voogt H.
    Eur Urol; 1998 Sep 01; 33(2):134-43. PubMed ID: 9519354
    [Abstract] [Full Text] [Related]

  • 16. Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group.
    Keuppens F, Whelan P, Carneiro de Moura JL, Newling D, Bono A, Denis L, Robinson M, Mahler C, Sylvester R, De Pauw M.
    Cancer; 1993 Dec 15; 72(12 Suppl):3863-9. PubMed ID: 8252505
    [Abstract] [Full Text] [Related]

  • 17. [Randomized study comparing zoladex versus zoladex plus flutamide in treatment of advanced cancer of the prostate].
    Haefliger JM.
    Helv Chir Acta; 1992 Oct 15; 59(3):477-83. PubMed ID: 1464545
    [Abstract] [Full Text] [Related]

  • 18. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
    Di Silverio F, Serio M, D'Eramo G, Sciarra F.
    Eur Urol; 1990 Oct 15; 18 Suppl 3():54-61. PubMed ID: 2151278
    [Abstract] [Full Text] [Related]

  • 19. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F, Holdaway IM, Haefliger JM, Jordaan JP.
    J Urol; 1991 Nov 15; 146(5):1321-6. PubMed ID: 1834864
    [Abstract] [Full Text] [Related]

  • 20. Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
    Bouffioux C.
    Eur Urol; 1988 Nov 15; 15(3-4):187-92. PubMed ID: 2975222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.